Do analysts rate DCOY or LTRN?

Decoy Therapeutics presently has a consensus target price of $30.00, indicating a potential upside of 2,652.29%. Given Decoy Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Decoy Therapeutics is more favorable than Lantern Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Decoy Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Lantern Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation and earnings, DCOY or LTRN?

Lantern Pharma is trading at a lower price-to-earnings ratio than Decoy Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Decoy Therapeutics N/A N/A -$12.52M -$30.37 N/A Lantern Pharma N/A N/A -$17.12M -$1.62 N/A

Is DCOY or LTRN more profitable?

Decoy Therapeutics' return on equity of -315.22% beat Lantern Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Decoy Therapeutics N/A -315.22% -167.15% Lantern Pharma N/A -368.02% -148.62%

Does the media refer more to DCOY or LTRN?

In the previous week, Lantern Pharma had 1 more articles in the media than Decoy Therapeutics. MarketBeat recorded 4 mentions for Lantern Pharma and 3 mentions for Decoy Therapeutics. Decoy Therapeutics' average media sentiment score of 1.26 beat Lantern Pharma's score of -0.07 indicating that Decoy Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Decoy Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lantern Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Do analysts prefer DCOY or TPST?

Decoy Therapeutics presently has a consensus target price of $30.00, suggesting a potential upside of 2,652.29%. Given Decoy Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Decoy Therapeutics is more favorable than Tempest Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Decoy Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Tempest Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has preferable valuation & earnings, DCOY or TPST?

Tempest Therapeutics is trading at a lower price-to-earnings ratio than Decoy Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Decoy Therapeutics N/A N/A -$12.52M -$30.37 N/A Tempest Therapeutics N/A N/A -$26.26M -$4.28 N/A

Is DCOY or TPST more profitable?

Decoy Therapeutics' return on equity of -315.22% beat Tempest Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Decoy Therapeutics N/A -315.22% -167.15% Tempest Therapeutics N/A -576.56% -134.99%

Does the media refer more to DCOY or TPST?

In the previous week, Tempest Therapeutics had 1 more articles in the media than Decoy Therapeutics. MarketBeat recorded 4 mentions for Tempest Therapeutics and 3 mentions for Decoy Therapeutics. Decoy Therapeutics' average media sentiment score of 1.26 beat Tempest Therapeutics' score of 0.95 indicating that Decoy Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Decoy Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tempest Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer DCOY or INAB?

Decoy Therapeutics currently has a consensus price target of $30.00, suggesting a potential upside of 2,652.29%. Given Decoy Therapeutics' higher possible upside, equities analysts clearly believe Decoy Therapeutics is more favorable than IN8bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Decoy Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 IN8bio 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger earnings and valuation, DCOY or INAB?

IN8bio is trading at a lower price-to-earnings ratio than Decoy Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Decoy Therapeutics N/A N/A -$12.52M -$30.37 N/A IN8bio N/A N/A -$19.44M -$1.01 N/A

Is DCOY or INAB more profitable?

IN8bio's return on equity of -93.66% beat Decoy Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Decoy Therapeutics N/A -315.22% -167.15% IN8bio N/A -93.66% -78.41%

Does the media refer more to DCOY or INAB?

In the previous week, IN8bio had 2 more articles in the media than Decoy Therapeutics. MarketBeat recorded 5 mentions for IN8bio and 3 mentions for Decoy Therapeutics. Decoy Therapeutics' average media sentiment score of 1.26 beat IN8bio's score of 1.09 indicating that Decoy Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Decoy Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive IN8bio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, DCOY or AEON?

AEON Biopharma is trading at a lower price-to-earnings ratio than Decoy Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Decoy Therapeutics N/A N/A -$12.52M -$30.37 N/A AEON Biopharma N/A N/A -$36.63M -$4.42 N/A

Is DCOY or AEON more profitable?

AEON Biopharma's return on equity of 0.00% beat Decoy Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Decoy Therapeutics N/A -315.22% -167.15% AEON Biopharma N/A N/A -994.63%

Does the media refer more to DCOY or AEON?

In the previous week, Decoy Therapeutics had 1 more articles in the media than AEON Biopharma. MarketBeat recorded 3 mentions for Decoy Therapeutics and 2 mentions for AEON Biopharma. Decoy Therapeutics' average media sentiment score of 1.26 beat AEON Biopharma's score of 0.00 indicating that Decoy Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Decoy Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AEON Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Decoy Therapeutics (DCOY) Competitors

$1.06 -0.04 (-3.21%)

Closing price 03:50 PM Eastern

Extended Trading

$1.06 +0.01 (+0.47%)

As of 06:13 PM Eastern

Compare

DCOY vs. BLRX, LTRN, TPST, INAB, and AEON

Should you buy Decoy Therapeutics stock or one of its competitors? Decoy Therapeutics's main competitors and comparable companies include BioLineRx (BLRX), Lantern Pharma (LTRN), Tempest Therapeutics (TPST), IN8bio (INAB), and AEON Biopharma (AEON). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Decoy Therapeutics compare to BioLineRx?

Decoy Therapeutics (NASDAQ:DCOY) and BioLineRx (NASDAQ:BLRX) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.

BioLineRx has higher revenue and earnings than Decoy Therapeutics. BioLineRx is trading at a lower price-to-earnings ratio than Decoy Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Decoy Therapeutics	N/A	N/A	-$12.52M	-$30.37	N/A
BioLineRx	$1.18M	6.35	-$1.17M	-$1.69	N/A

11.9% of Decoy Therapeutics shares are owned by institutional investors. Comparatively, 1.6% of BioLineRx shares are owned by institutional investors. 1.5% of Decoy Therapeutics shares are owned by insiders. Comparatively, 1.1% of BioLineRx shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Decoy Therapeutics had 2 more articles in the media than BioLineRx. MarketBeat recorded 3 mentions for Decoy Therapeutics and 1 mentions for BioLineRx. BioLineRx's average media sentiment score of 1.79 beat Decoy Therapeutics' score of 1.26 indicating that BioLineRx is being referred to more favorably in the news media.

Company	Overall Sentiment
Decoy Therapeutics	Positive
BioLineRx	Very Positive

Decoy Therapeutics presently has a consensus target price of $30.00, suggesting a potential upside of 2,652.29%. Given Decoy Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Decoy Therapeutics is more favorable than BioLineRx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Decoy Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
BioLineRx	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Decoy Therapeutics has a beta of 0.76, indicating that its stock price is 24% less volatile than the broader market. Comparatively, BioLineRx has a beta of 1.64, indicating that its stock price is 64% more volatile than the broader market.

Decoy Therapeutics has a net margin of 0.00% compared to BioLineRx's net margin of -502.08%. BioLineRx's return on equity of -34.80% beat Decoy Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Decoy Therapeutics	N/A	-315.22%	-167.15%
BioLineRx	-502.08%	-34.80%	-18.27%

Summary

Decoy Therapeutics and BioLineRx tied by winning 7 of the 14 factors compared between the two stocks.

How does Decoy Therapeutics compare to Lantern Pharma?

Decoy Therapeutics (NASDAQ:DCOY) and Lantern Pharma (NASDAQ:LTRN) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability, media sentiment and earnings.

Decoy Therapeutics has a beta of 0.76, suggesting that its share price is 24% less volatile than the broader market. Comparatively, Lantern Pharma has a beta of 2.48, suggesting that its share price is 148% more volatile than the broader market.

In the previous week, Lantern Pharma had 1 more articles in the media than Decoy Therapeutics. MarketBeat recorded 4 mentions for Lantern Pharma and 3 mentions for Decoy Therapeutics. Decoy Therapeutics' average media sentiment score of 1.26 beat Lantern Pharma's score of -0.07 indicating that Decoy Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Decoy Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lantern Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Lantern Pharma is trading at a lower price-to-earnings ratio than Decoy Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Decoy Therapeutics	N/A	N/A	-$12.52M	-$30.37	N/A
Lantern Pharma	N/A	N/A	-$17.12M	-$1.62	N/A

Decoy Therapeutics' return on equity of -315.22% beat Lantern Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Decoy Therapeutics	N/A	-315.22%	-167.15%
Lantern Pharma	N/A	-368.02%	-148.62%

11.9% of Decoy Therapeutics shares are held by institutional investors. Comparatively, 28.6% of Lantern Pharma shares are held by institutional investors. 1.5% of Decoy Therapeutics shares are held by company insiders. Comparatively, 8.8% of Lantern Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Decoy Therapeutics presently has a consensus target price of $30.00, indicating a potential upside of 2,652.29%. Given Decoy Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Decoy Therapeutics is more favorable than Lantern Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Decoy Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Lantern Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Decoy Therapeutics and Lantern Pharma tied by winning 6 of the 12 factors compared between the two stocks.

How does Decoy Therapeutics compare to Tempest Therapeutics?

Decoy Therapeutics (NASDAQ:DCOY) and Tempest Therapeutics (NASDAQ:TPST) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, dividends, valuation, earnings, profitability, risk, institutional ownership and media sentiment.

Decoy Therapeutics' return on equity of -315.22% beat Tempest Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Decoy Therapeutics	N/A	-315.22%	-167.15%
Tempest Therapeutics	N/A	-576.56%	-134.99%

Decoy Therapeutics presently has a consensus target price of $30.00, suggesting a potential upside of 2,652.29%. Given Decoy Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Decoy Therapeutics is more favorable than Tempest Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Decoy Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Tempest Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

11.9% of Decoy Therapeutics shares are owned by institutional investors. Comparatively, 22.5% of Tempest Therapeutics shares are owned by institutional investors. 1.5% of Decoy Therapeutics shares are owned by insiders. Comparatively, 31.5% of Tempest Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Tempest Therapeutics had 1 more articles in the media than Decoy Therapeutics. MarketBeat recorded 4 mentions for Tempest Therapeutics and 3 mentions for Decoy Therapeutics. Decoy Therapeutics' average media sentiment score of 1.26 beat Tempest Therapeutics' score of 0.95 indicating that Decoy Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Decoy Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tempest Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Decoy Therapeutics has a beta of 0.76, meaning that its stock price is 24% less volatile than the broader market. Comparatively, Tempest Therapeutics has a beta of -1.54, meaning that its stock price is 254% less volatile than the broader market.

Tempest Therapeutics is trading at a lower price-to-earnings ratio than Decoy Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Decoy Therapeutics	N/A	N/A	-$12.52M	-$30.37	N/A
Tempest Therapeutics	N/A	N/A	-$26.26M	-$4.28	N/A

Summary

Decoy Therapeutics beats Tempest Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Decoy Therapeutics compare to IN8bio?

Decoy Therapeutics (NASDAQ:DCOY) and IN8bio (NASDAQ:INAB) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, profitability, valuation, risk, institutional ownership and dividends.

IN8bio is trading at a lower price-to-earnings ratio than Decoy Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Decoy Therapeutics	N/A	N/A	-$12.52M	-$30.37	N/A
IN8bio	N/A	N/A	-$19.44M	-$1.01	N/A

IN8bio's return on equity of -93.66% beat Decoy Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Decoy Therapeutics	N/A	-315.22%	-167.15%
IN8bio	N/A	-93.66%	-78.41%

11.9% of Decoy Therapeutics shares are owned by institutional investors. Comparatively, 92.1% of IN8bio shares are owned by institutional investors. 1.5% of Decoy Therapeutics shares are owned by company insiders. Comparatively, 14.5% of IN8bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Decoy Therapeutics has a beta of 0.76, meaning that its share price is 24% less volatile than the broader market. Comparatively, IN8bio has a beta of 0.27, meaning that its share price is 73% less volatile than the broader market.

In the previous week, IN8bio had 2 more articles in the media than Decoy Therapeutics. MarketBeat recorded 5 mentions for IN8bio and 3 mentions for Decoy Therapeutics. Decoy Therapeutics' average media sentiment score of 1.26 beat IN8bio's score of 1.09 indicating that Decoy Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Decoy Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
IN8bio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Decoy Therapeutics currently has a consensus price target of $30.00, suggesting a potential upside of 2,652.29%. Given Decoy Therapeutics' higher possible upside, equities analysts clearly believe Decoy Therapeutics is more favorable than IN8bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Decoy Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
IN8bio	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

IN8bio beats Decoy Therapeutics on 6 of the 10 factors compared between the two stocks.

How does Decoy Therapeutics compare to AEON Biopharma?

Decoy Therapeutics (NASDAQ:DCOY) and AEON Biopharma (NASDAQ:AEON) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, institutional ownership, media sentiment and valuation.

Decoy Therapeutics presently has a consensus target price of $30.00, suggesting a potential upside of 2,652.29%. AEON Biopharma has a consensus target price of $1.67, suggesting a potential upside of 872.38%. Given Decoy Therapeutics' higher possible upside, equities research analysts plainly believe Decoy Therapeutics is more favorable than AEON Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Decoy Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
AEON Biopharma	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

11.9% of Decoy Therapeutics shares are owned by institutional investors. Comparatively, 22.8% of AEON Biopharma shares are owned by institutional investors. 1.5% of Decoy Therapeutics shares are owned by insiders. Comparatively, 9.4% of AEON Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

AEON Biopharma's return on equity of 0.00% beat Decoy Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Decoy Therapeutics	N/A	-315.22%	-167.15%
AEON Biopharma	N/A	N/A	-994.63%

Decoy Therapeutics has a beta of 0.76, meaning that its share price is 24% less volatile than the broader market. Comparatively, AEON Biopharma has a beta of 0.68, meaning that its share price is 32% less volatile than the broader market.

AEON Biopharma is trading at a lower price-to-earnings ratio than Decoy Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Decoy Therapeutics	N/A	N/A	-$12.52M	-$30.37	N/A
AEON Biopharma	N/A	N/A	-$36.63M	-$4.42	N/A

In the previous week, Decoy Therapeutics had 1 more articles in the media than AEON Biopharma. MarketBeat recorded 3 mentions for Decoy Therapeutics and 2 mentions for AEON Biopharma. Decoy Therapeutics' average media sentiment score of 1.26 beat AEON Biopharma's score of 0.00 indicating that Decoy Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Decoy Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AEON Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Decoy Therapeutics and AEON Biopharma tied by winning 6 of the 12 factors compared between the two stocks.

Get Decoy Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DCOY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DCOY vs. The Competition

Export

Metric	Decoy Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.52M	$4.12B	$7.85B	$12.19B
Dividend Yield	N/A	3.63%	2.45%	4.52%
P/E Ratio	-0.03	25.05	34.98	30.75
Price / Sales	N/A	14.82	8.10	5.42
Price / Cash	N/A	26.63	22.08	22.51
Price / Book	0.10	4.10	4.43	3.77
Net Income	-$12.52M	-$22.78M	$3.51B	$390.82M
7 Day Performance	-5.80%	0.82%	0.40%	1.59%
1 Month Performance	-26.22%	-7.86%	-5.04%	-6.86%
1 Year Performance	N/A	-3.48%	-0.89%	-7.24%

Decoy Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DCOY Decoy Therapeutics	2.7478 of 5 stars	$1.06 -3.2%	$30.00 +2,743.6%	N/A	$2.52M	N/A	N/A	11	Positive News Earnings Report Gap Down
BLRX BioLineRx	0.747 of 5 stars	$1.71 -3.3%	N/A	-54.9%	$9.76M	$1.18M	N/A	22	Gap Down
LTRN Lantern Pharma	0.32 of 5 stars	$0.57 +6.7%	N/A	-86.4%	$9.56M	N/A	N/A	16	Analyst Downgrade Short Interest Increase Gap Up
TPST Tempest Therapeutics	1.4179 of 5 stars	$0.38 +1.4%	N/A	-95.9%	$9.44M	N/A	N/A	4	News Coverage Gap Up
INAB IN8bio	2.0556 of 5 stars	$0.93 +11.6%	N/A	-48.1%	$8.97M	N/A	N/A	18	Positive News Earnings Report Short Interest Decrease Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DCOY) was last updated on 11/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Decoy Therapeutics (DCOY) Competitors

DCOY vs. BLRX, LTRN, TPST, INAB, and AEON

How does Decoy Therapeutics compare to BioLineRx?

Summary

How does Decoy Therapeutics compare to Lantern Pharma?

Summary

How does Decoy Therapeutics compare to Tempest Therapeutics?

Summary

How does Decoy Therapeutics compare to IN8bio?

Summary

How does Decoy Therapeutics compare to AEON Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DCOY vs. The Competition

Decoy Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Decoy Therapeutics (DCOY) Competitors

DCOY vs. BLRX, LTRN, TPST, INAB, and AEON

How does Decoy Therapeutics compare to BioLineRx?

Which has preferable earnings and valuation, DCOY or BLRX?

Do institutionals and insiders hold more shares of DCOY or BLRX?

Does the media favor DCOY or BLRX?

Do analysts rate DCOY or BLRX?

Which has more volatility & risk, DCOY or BLRX?

Is DCOY or BLRX more profitable?

Summary

How does Decoy Therapeutics compare to Lantern Pharma?

Which has more risk & volatility, DCOY or LTRN?

Does the media refer more to DCOY or LTRN?

Which has higher valuation and earnings, DCOY or LTRN?

Is DCOY or LTRN more profitable?

Do institutionals and insiders have more ownership in DCOY or LTRN?

Do analysts rate DCOY or LTRN?

Summary

How does Decoy Therapeutics compare to Tempest Therapeutics?

Is DCOY or TPST more profitable?

Do analysts prefer DCOY or TPST?

Do institutionals & insiders hold more shares of DCOY or TPST?

Does the media refer more to DCOY or TPST?

Which has more risk & volatility, DCOY or TPST?

Which has preferable valuation & earnings, DCOY or TPST?

Summary

How does Decoy Therapeutics compare to IN8bio?

Which has stronger earnings and valuation, DCOY or INAB?

Is DCOY or INAB more profitable?

Do institutionals and insiders hold more shares of DCOY or INAB?

Which has more risk and volatility, DCOY or INAB?

Does the media refer more to DCOY or INAB?

Do analysts prefer DCOY or INAB?

Summary

How does Decoy Therapeutics compare to AEON Biopharma?

Do analysts prefer DCOY or AEON?

Do institutionals & insiders hold more shares of DCOY or AEON?

Is DCOY or AEON more profitable?

Which has more volatility and risk, DCOY or AEON?

Which has better valuation and earnings, DCOY or AEON?

Does the media refer more to DCOY or AEON?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DCOY vs. The Competition

Decoy Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools